Suven's Alzheimer's molecule fails to meet primary end point in phase-2 trial

SUVN-502's clinical trial data assumed significance as no new Alzheimer's drug has been approved since Forest Labs' Namenda in 2003

from Moneycontrol https://ift.tt/37SvPmC